Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buloxibutid in Raynaud's Phenomenon secondary to Systemic Sclerosis
NCT04388176Phase 2Completed
- Sponsor
- Vicore Pharma
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buloxibutid in Raynaud phenomenon, sponsored by Vicore Pharma. Started Jan 2020; status: completed.
02
Drugs
buloxibutid
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT04388176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388176.